[A26-72] Atogepant (migraine, acute treatment) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2026
Project no.:
A26-72
Commission:
Commission awarded on 19.06.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults with migraine with or without aura who require acute treatment
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI:
https://doi.org/10.60584/A26-72
| Project no. | Title | Status |
|---|---|---|
| A25-38 | Atogepant (migraine) – Benefit assessment according to §35a Social Code Book V | Commission completed |